Susanna Asseyer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/616941/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Uncovering convolutional neural network decisions for diagnosing multiple sclerosis on conventional MRI using layer-wise relevance propagation. NeuroImage: Clinical, 2019, 24, 102003.	1.4	93
2	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1:ÂResults from 163 lumbar punctures in 100 adult patients. Journal of Neuroinflammation, 2020, 17, 261.	3.1	84
3	Sex differences in brain atrophy in multiple sclerosis. Biology of Sex Differences, 2020, 11, 49.	1.8	51
4	Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Journal of Neuroinflammation, 2021, 18, 105.	3.1	44
5	Prodromal headache in MOG-antibody positive optic neuritis. Multiple Sclerosis and Related Disorders, 2020, 40, 101965.	0.9	41
6	Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	41
7	Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731879668.	0.5	40
8	Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. Frontiers in Neurology, 2020, 11, 778.	1.1	37
9	Normative Data and Minimally Detectable Change for Inner Retinal Layer Thicknesses Using a Semi-automated OCT Image Segmentation Pipeline. Frontiers in Neurology, 2019, 10, 1117.	1.1	36
10	Standardization of T1w/T2w Ratio Improves Detection of Tissue Damage in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 334.	1.1	31
11	Increased Serum Neurofilament Light and Thin Ganglion Cell–Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	29
12	Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study. Pain, 2020, 161, 787-796.	2.0	29
13	Evaluation of the â€~ring sign' and the â€~core sign' as a magnetic resonance imaging marker of disease activity and progression in clinically isolated syndrome and early multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732091548.	0.5	25
14	Attack-related damage of thalamic nuclei in neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1156-1164.	0.9	20
15	Anti-MOG antibody–associated disorders: differences in clinical profiles and prognosis in Japan and Germany. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 377-383.	0.9	18
16	Impact of treatment on cellular immunophenotype in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	17
17	Imaging markers of disability in aquaporin-4 immunoglobulin G seropositive neuromyelitis optica: a graph theory study. Brain Communications, 2019, 1, fcz026.	1.5	15
18	Ventral posterior nucleus volume is associated with neuropathic pain intensity in neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2020, 46, 102579	0.9	14

SUSANNA ASSEYER

#	Article	IF	CITATIONS
19	Differences in Advanced Magnetic Resonance Imaging in MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders: A Comparative Study. Frontiers in Neurology, 2020, 11, 499910.	1.1	14
20	Foveal changes in aquaporinâ€4 antibody seropositive neuromyelitis optica spectrum disorder are independent of optic neuritis and not overtly progressive. European Journal of Neurology, 2021, 28, 2280-2293.	1.7	14
21	Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 1859-1870.	1.4	14
22	Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation. Multiple Sclerosis Journal, 2021, 27, 2180-2190.	1.4	12
23	Pain, depression, and quality of life in adults with MOGâ€antibody–associated disease. European Journal of Neurology, 2021, 28, 1645-1658.	1.7	11
24	Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder. Frontiers in Neurology, 2021, 12, 635419.	1.1	11
25	Blunted neural and psychological stress processing predicts future grey matter atrophy in multiple sclerosis. Neurobiology of Stress, 2020, 13, 100244.	1.9	10
26	Optic chiasm measurements may be useful markers of anterior optic pathway degeneration in neuromyelitis optica spectrum disorders. European Radiology, 2020, 30, 5048-5058.	2.3	9
27	Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study. NeuroImage: Clinical, 2021, 30, 102608.	1.4	9
28	Central stress processing, T-cell responsivity to stress hormones and disease severity in multiple sclerosis. Brain Communications, 2022, 4, fcac086.	1.5	7
29	AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110068.	0.5	6
30	Prefrontal-amygdala emotion regulation and depression in multiple sclerosis. Brain Communications, 2022, 4, .	1.5	5
31	Practical recognition tools of immunoglobulinÂG serum antibodies against the myelin oligodendrocyte glycoproteinâ€positive optic neuritis and its clinical implications. Clinical and Experimental Neuroimmunology, 2021, 12, 42-53.	0.5	4
32	Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2022, 28, 757-767.	1.4	3